1. Characteristics of KRAS and BRAF Genes, MMR Protein Expression Status, and MMR Genes in Colorectal Cancer Patients

Bui Bích Mai, Pham Cam Phuong, Doan Thi Kim Phuong

Main Article Content

Abstract

This study describes the characteristics and variants of KRAS and BRAF genes, as well as the status of MMR protein expression and MMR genes in Vietnamese patients with colorectal cancer. The patients were diagnosed with colorectal cancer at the Nuclear Medicine and Oncology Center, Bach Mai Hospital, from January 2022 to June 2023. The study employed a descriptive, retrospective, and prospective combined method with a whole-sample approach. In the study of 219 colorectal cancer cases, we observed KRAS and BRAF mutation rates of 47.9% and 5.9%, respectively; MMR protein loss rates of 15.1%; and identified 8 variants in the MMR genes associated with Lynch syndrome. The study found a significant association between gender and KRAS gene mutations, with females having a 2.34-fold higher risk of KRAS mutations compared to males. There was also a statistically significant association between the loss of MMR protein expression (dMMR) and age under 60, a family history of Lynch syndrome, mucinous adenocarcinoma histology, and rectal tumor location.

Article Details

References

1. Sokolenko AP, Imyanitov EN, et al. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018; 5: 76.
2. Garcia-Carbonero N, Martinez-Useros J, et al. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: A single institutional study. Cells. 2020; 9(1): 219.
3. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị ung thư đại trực tràng. 2018.
4. Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors. Cancers (Basel). 2021; 13(3): 467. Published 2021 Jan 26. doi:10.3390/cancers13030467.
5. Jelski W, Mroczko B. Biochemical Markers of Colorectal Cancer – Present and Future. Cancer Manag Res. 2020; 12: 4789-4797.
6. Dinu D, Dobre M, Panaitescu E, et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. J Med Life. 2014; 7(4): 581-587.
7. Trọng Hòa N, Lê Huy T. Mối liên quan giữa tình trạng đột biến gen KRAS, NRAS, BRAF và một số đặc điểm bệnh học ung thư biểu mô đại trực tràng giai đoạn di căn. VMJ. 2021; 506(1).
8 .Ngô Thị Hoài, Mai Hồng Bàng, Lê Hữu Song và CS. Đặc điểm giải phẫu bệnh và một số yếu tố liên quan đến đột biến KRAS, BRAF ở bệnh nhân ung thư đại trực tràng. Tạp chí Y dược lâm sàng 108. 2022: 4(17): 112-119.
9. Carlos G. M. Ferreira et al. Frequency of KRAS mutations in female colorectal cancer (CRC) patients: Findings of a Brazilian cohort of 8,234 cases. JCO. 2012. 30, e14101-e14101.
10. Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol. 2016; 7(5): 687-704.
11. Ioana M, Angelescu C, Burada F, et al. MMR gene expression pattern in sporadic colorectal cancer. J Gastrointestin Liver Dis. 2010; 19(2): 155-159.
12. Vũ Thị Thu Hảo, Phạm Văn Tuyến, Trần Văn Chương và CS. Nghiên cứu tình trạng bộc lộ protein MMR ở bệnh nhân ung thư biểu mô đại trực tràng tại Bệnh viện Bạch Mai. Vietnam Medical Journal. 2023; 553(1B): 256-259.
13. Li Y, Fan L, Zheng J, et al. Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer. Cancer Biol Med. 2022; 19(8): 1235-1248. doi:10.20892/j.issn.2095-3941.2021.0585.
14. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6): 2073-2087.e3. doi:10.1053/j.gastro.2009.12.064.
15. Liang Y, Cai X, Zheng X, Yin H. Analysis of the Clinicopathological Characteristics of Stage I-III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins. Onco Targets Ther. 2021; 14:2203-2212. doi:10.2147/OTT.S278029.